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Summary
Objectives: We sought to modify the Serodia HIV-1/HIV-2 particle agglutination assay (PA), a
simple and cost-effective HIV assay that is used globally for the detection of HIV antibodies, as a
sensitive/less sensitive test (S/LS) to identify recently infected individuals and to estimate HIV
incidence.
Methods: The Serodia PA test was modified as an S/LS test (PA-LS) by using HIV antigen-coated
gelatin particles at a dilution of 1:68 and a specific diluent, and calibrated using 37 HIV clade B
seroconversion panels (309 samples) from Trinidad and from a commercial source that were
tested at dilution intervals from 1:10 to 1:80 000. The greatest sensitivity for correctly classifying
samples from recent and established infections was determined by receiver operator curve (ROC)
analysis.
Results: At a 1:40 000 sample dilution and a days post-seroconversion cutoff of 190 days, the PA-
LS test yielded a 97% sensitivity for classifying recent and established infection samples.
Furthermore, at a 1:20 000 dilution, the positive predictive value for correctly identifying
recently infected individuals was 99%. The PA-LS test offers a 30—44-fold cost saving over
currently available S/LS tests.
Conclusion: Amodified, low cost and simple-to-perform PA test is appropriate for use in resource-
limited countries, and has exhibited excellence in distinguishing recent from established HIV
infection.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 410 706 2788; fax: +1 410 706 2789.
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The ability to classify HIV-1 infections into phases of
recent versus established infection is important for thePublished by Elsevier Ltd. All rights reserved.
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veys, for assessing the dynamics of the epidemic, and for
determining the effectiveness of efforts to reduce HIV
transmission in high-risk populations. Currently, sensi-
tive/less sensitive (S/LS) tests are not indicated for patient
management (STARHS Workshop, Toronto, 2006). S/LS
assays have allowed the estimation of HIV incidence with-
out the time and resources necessary to follow a cohort of
high-risk seronegative individuals, and have the ability to
discriminate between recent and established infection
samples with 83—97% accuracy.1 S/LS serologic testing
strategies have been developed and validated for HIV clade
B infections; additionally, one assay has been validated for
clades B, E, C, and AD.2
Since 1998, a number of S/LS ELISA methods have been
developed, and these are based on the concept that antibody
titers rise during the first 6 months of infection. Included are
the Abbott 3A11 EIA (Abbott Laboratories, Abbott Park, IL),3
and the Vironostika HIV-1 Microelisa (Dilutional Vironostika
(DV), Biomerieux, Durham, NC);4,5 rapid HIV tests have also
shown encouraging results.1,6 Another HIV-1 ELISA (Genetic
Systems rLAV EIA, Bio-Rad) also acts as an S/LS assay, but
exploits the concept of the changing avidity of HIVantibodies
throughout infection.7
Currently used S/LS tests have characteristics that limit
their use in resource-poor countries. For example, they
require relatively complex laboratory instrumentation,
which limits their use in settings where stable electricity
and sound laboratory infrastructure are lacking. In addition,
they require a degree of technical expertise that may be
unavailable in a majority of laboratories, and the cost of the
test is relatively high.
A particle agglutination (PA) test, the Serodia HIV-1/2 test
(Fujirebio, Inc., Tokyo, Japan), is a low-cost, simple-to-per-
form agglutination assay capable of detecting antibodies to
HIV-1 and HIV-2. The test incorporates viral lysate antigens
coated on gelatin microbeads (particles) that agglutinate in
the presence of specific antibodies.
Because of the widespread use of the Serodia HIV-1/2 PA
assay in Asia, Africa, and South America, its technical
simplicity, its applicability in laboratories that cannot sup-
port ELISA technology, and its low cost, we sought to
exploit this assay to develop an S/LS test method that
could be used in a much wider variety of testing venues.
In this report, we describe the modification of the Serodia
HIV-1/2 PA assay to act as a sensitive/less-sensitive assay
(PA S/LS) to differentiate recent from established HIV
infection.
Methods
Modification of the Serodia HIV-1/2 PA (sensitive
PA assay)
The commercially marketed Serodia HIV-1/2 PA assay was
first modified for cost savings before being further modified
to act as an S/LS test. The modification included diluting the
antigen-coated particles 1:68 in PBS, adding 38 ml of this
reagent and 8 ml of the test sample diluted 1:10 using Dilsim
(Organon Tecknika, Durham, NC) into a microtiter plate.
Based on the presence or absence of agglutination, results
were interpreted as positive or negative. This modifiedSerodia HIV-1/2 PA method was considered as the sensitive
(PA-S) version of the PA S/LS test.
Validation of the specificity and epidemiologic/
analytical sensitivities of the PA-S test
To ensure that the PA-S assay did not lose sensitivity and
specificity for correctly determining HIV status as a result of
the cost-saving modifications, a total of 990 HIV negative and
200 Western blot confirmed HIV positive samples from the
USA were tested to determine the specificity and epidemio-
logic sensitivity, respectively, of the PA-S test. Samples that
produced positive results were repeated using unsensitized
(uncoated) particles to rule out reactivity to the gelatin
particles themselves; those that exhibited a positive result
with the unsensitized particles were considered as producing
invalid results and were not included in the analysis. Analy-
tical sensitivity was determined using 83 members from 12
seroconversion panels (Boston Biomedica, Inc., BBI, West
Bridgeport, MA), and 13 HIV weak positive samples (as
determined by their Western blot profiles). Analytical sensi-
tivity using the panels was determined by comparing the PA-S
results with the results from the most sensitive EIAs used to
characterize each panel. All samples were tested in a blinded
fashion.
Samples for calibrating the PA-LS test
Two hundred and seventy-nine samples from 25 HIV-1 clade B
seroconverters from Trinidad, and 30 samples from 12 BBI
HIV-1 clade B seroconversion panels (total of 309 samples
from 37 seroconverters) were used to calibrate the PA-LS
test. The Trinidad seroconverters had been previously iden-
tified by the presence of p24 antigenemia in the absence of
antibody, followed by subsequent seroconversion or through
interval seroconversion during a one-year intensive follow-up
of high-risk patients with genital ulcer disease. The sampling
methods for this study have been previously reported.8,9 The
approximate date of seroconversion was imputed as the
midpoint date between the last antibody negative and first
antibody positive bleed, as measured by several antibody
EIAs. The selection of the date of seroconversion was aided by
the emergingWestern blot profiles and, in the instance where
no serology results were available, by the date of the appear-
ance of HIV RNA plus 15 days.
Calibration procedure for the PA-LS test
The PA-S test was further modified in order to calibrate it for
use as an LS test. Modifications included using the 1:68
dilution of HIV-1 antigen-coated particles, and assessing
different sample dilutions, different particle reagent and
sample volumes, and different incubation times before read-
ing. The sample dilutions were made in Dilsim rather than the
diluent supplied with the test kit, and samples were diluted
at 1:10, 1:100, 1:1000, 1:10 000, 1:20 000, 1:40 000,
1:48 000, 1:58 000, 1:68 000, and 1:80 000. The last dilution
that produced a positive reaction (1+) by the PA-LS test
constituted the endpoint dilution (ED), and this was assessed
for all members of the 37 panels. The parameters that
exhibited the maximum correct classifications of recent
and established HIV infection samples as compared with
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Figure 1 Typical reactions of the PA-LS test. A pink/red ‘but-
ton’ of any size or intensity in the well of the ELISA plate
constitutes a negative result, while agglutination (dispersed
particles) represents a positive result. Samples in rows F, G
and H at the 1:40 000 dilution represent recent HIV infection
and are typical negative results. Samples in rows F, G, and H at
the 1:10 000 and 1:20 000 dilutions also are negative results.
Samples in all other wells represent typical positive results, and
in particular, those in rows D and E at the 1:40 000 dilution
represent established HIV infection.the known times of infection of the panel members were
selected for the PA-LS test procedure.
With the knowledge that each seroconversion panel con-
tributedvaryingnumbersof specimens inthisanalysis,andthat
inter-panel readingswere not independent,wealso selected a
single specimen from each panel to analyze in a manner that
gave thebest continuumofdays post-seroconversion, aswould
be expected in a cross-sectional pool of independent, seropo-
sitive specimens of unknown times from infection.
Concordance studies
A comparison study was conducted to determine the con-
cordance of the PA-LS test with the reference Dilutional
Vironostika S/LS (DV). A subset (n = 181) of the 279 members
of the 25 Trinidad seroconversion panels used to calibrate the
PA-LS test was tested by both assays. Concordance was
determined at the optimal parameters of the PA-LS test
identified during the calibration phase, and at the standar-
dized optical density (SOD) cutoff of 1.0 for the DV test.
Reproducibility studies
To assess the reproducibility of the PA-LS test, a total of 15
archived samples with unknown times of infection were
selected; these consisted of five samples clearly identified
by the PA-LS assay as being from recently infected persons,
five samples clearly identified as being from persons with
established infection, and five borderline samples classified
as recent (negative) at the sample dilution of 1:40 000, but
positive at the 1:20 000 dilution. To determine the reprodu-
cibility of results between runs (inter-run reproducibility),
each sample was tested in a blinded fashion at dilutions from
1:10 to 1:68 000 over three consecutive days, and results
were compared for each corresponding dilution. Additionally,
the 15 samples were repeatedly tested 11 times each by the
PA-LS to determine the reproducibility of results within a run
(intra-run reproducibility). Also, inter-rater reliability was
assessed by comparing the agglutination reactions scored
independently by two technicians.
Statistical analysis
Receiver operator curve (ROC) analysis, a medical data ana-
lysis tool widely utilized to study the effect of varying the
threshold on the numerical outcomeof a diagnostic test,10was
used to determine the most parsimonious days post-serocon-
version cutoff that yielded the greatest sensitivity for cor-
rectly classifying recent and established infection samples.
Inter-rater variation was assessed by Chi-square analyses
and by computing the kappa statistic (measure of agree-
ment). Reproducibility was assessed by the computation of
the coefficients of variation (CV).
Results
Sensitivity and specificity of the modified PA-S
assay
With cost savings being one of the major objectives of the
development of the PA-LS test, the routine Serodia HIV-1/2 PA
assay was initially modified by diluting the antigen to variousconcentrations, and its sensitivity and specificity were
assessed at each dilution. The optimal antigen dilution of
the particle reagent at which there was no loss of sensitivity
and minimal loss of specificity was determined to be 1:68.
Under these conditions, the PA-S correctly identified 200/200
(100% sensitivity) of the HIV-1 Western blot positive samples
and 978/990 (98.8% specificity) of the HIV negative speci-
mens. Ten of the 12 HIV negative samples that produced
discordant (initially positive) results by the PA-S also pro-
duced positive results when re-tested using unsensitized
particles; the remaining two samples produced borderline
(+/) results. Therefore, the results from 10 samples were
considered invalid, and the actual specificity of the PA-S was
then determined to be 99.8%. When assessing the analytical
sensitivity using 83 members of 12 BBI seroconversion panels
in comparison with the most sensitive ELISA used to char-
acterize the 12 panels, the PA-S test detected infection
earlier (by one bleed) in 3/12 panels, later (by one and
two bleeds) in two panels, and at the same time in seven
panels. Moreover, all of the 13 weak HIV-1 Western blot
positive samples were classified as positive by the PA-S.
Performance of the PA-LS assay
Typical reactions by the PA-LS are depicted in Figure 1.
Parameters that were selected included a particle reagent
volume of 38 ml, a sample volume of 8 ml, and a reading of
results time between 6 and 48 hours. Figure 2 shows the
sensitivity rates of the PA-LS at three candidate sample
dilutions (1:40 000, 1:48 000 and 1:58 000) for recent and
established infections. These dilutions were chosen as they
yielded the highest rates of sensitivity for correctly classify-
ing known recent and known established seroconversion
panel samples. Although the 1:58 000 dilution exhibited
the highest sensitivity (98%) for classifying recently infected
462 H. Li et al.
Figure 2 Sensitivity of the PA-LS for known recent and established infection samples by days post-seroconversion at various PA
sample dilutions. Each data point represents multiple samples at their respective days post-seroconversion.samples between 80 and 160 days post-seroconversion, the
1:40 000 dilution gave the highest collective sensitivity for
recent and established infection samples corresponding to
190 days post-seroconversion. As shown in Table 1, 100/103
samplemembers known to be from recently infected patients
(190 days post-seroconversion) were classified correctly by
the PA-LS test, thereby yielding a sensitivity for recent
infections of 97.1%; three samples were misclassified (spe-
cificity for recent infections of 96.6%). Similarly, 199/206
specimens known to be from persons with established infec-
tions (>190 days post-seroconversion) were correctly classi-
fied by the PA-LS, yielding a sensitivity of 96.6%; seven
samples were misclassified (specificity for established infec-
tions of 97.1%). One of these seven samples was from an AIDS
case, yielding a misclassification rate of 4% among 25 AIDS
case samples tested. Figure 3 shows the demarcation point
(window period) using the 1:40 000 sample dilution for recent
and established infection samples.
Ranges of days post-seroconversion of the samples
included in the sensitivity analyses were 0—2709 days (inter-
quartile range (IQR) = 75, 1569). Each panel contributed an
average of 8.35 members (range 1—20). Random selection ofTable 1 Performance of the PA-LS assay as determined by seroc
Recent by known days post-SC (190 days post-SC)
Established by known days post-SC (>190 days post-SC)
SC, seroconversion.single specimens from each panel resulted in a near normal
distribution of days post-seroconversion with a range of 1—
2287, (IQR = 13, 748) (data not shown). Analysis of these
independent readings resulted in the correct classification
of 18/18 specimens known to be recent (190 days) and 19/
19 specimens that were known to be established (>190 days)
at the 1:40 000 and 1:48 000 dilutions.
Reproducibility studies
Intra-run, inter-run, and inter-rater analyses revealed a 100%
agreement of the binary ED readings (agglutination vs. no
agglutination) of the samples used for reproducibility when
tested in a blinded fashion across each stratum. In addition,
all results were reproducible when 1:40 000 dilutions of the
15 samples were tested 11 times in the same run.
Concordance between the DV and the PA-LS assay
The concordance between the PA-LS assay (at the 1:40 000
dilution) and the DV S/LS assay (at the 1.0 SOD cutoff) using a
subset (n = 181) of the seroconversion sample members fromonversion samples, N = 309
Recent by PA-LS Established by PA-LS
100/103 (97.1%) 3/103 (2.9%)
7/206 (3.4%) 199/206 (96.6%)
Simple test to determine recent HIV infection 463
Figure 3 Selection of demarcation point (window period) using
optimal sensitivity (at 1:40 000 sample dilution) for recent and
established infection samples.Trinidad was found to be 60% for recent infection samples,
and 73% for established infection samples. The DV S/LS
correctly classified 83% of recent and 54% of established
infection samples, compared with 98% of these recent and
93% of established infection samples when testing the same
subset by the PA-LS.
Discussion
HIV incidence estimations using S/LS testing strategies are
easily performed and provide useful information for public
health intervention and prevention programs by identifying
high-incident populations for targeting.11,12 In addition to
surveillance, an important potential application of S/LS
testing is in clinical settings where knowledge of when a
patient was infected can assist healthcare professionals in
making important decisions regarding appropriate behavioral
intervention, contact tracing, and treatment options. The
purpose of this study was to develop an alternative S/LS assayTable 2 Comparison of procedures and costs of LS assays previo
Vironostika LS BED
Calibrator 1:20 000 1:10
Control dilution (1:76) 1:10
Sample dilution 1:20 000 1:10
Sample incubation 20 min at 37 8C 1 h a
Wash No. 1 4 4
Conjugate incubation 20 min at 37 8C 1 h a
Wash No. 2 4 4
Substrate incubation 10 min at 15—30 8C 15 m
Stop solution Required Requ
Read results Immediately Imm
Calculation Required Requ
Interpretation as recent SOD <1.0 ODn
Format 96-well EIA plate 96-w
Incubator, reader, washer Yes Yes
No. controls and calibrators/run 12 11
No. of wells per sample 3 4
Cost per sample $3 ($1 per well) $2.7
EIA, enzyme immunoassay; CEIA, capture EIA; SOD = standardized optithat does not require sophisticated instrumentation and
infrastructure to determine recent or established HIV infec-
tion. Once the test is fully calibrated and validated, it would
be appropriate to evaluate it in cross-sectional surveillance
situations before making a conclusion as to the utility of the
assay for determining the incidence of HIV in persons at all
stages of infection, including those with late stage disease
and those on antiretroviral therapy (ART).
The currently available S/LS tests are ELISA methods that
require instrumentation and a certain degree of technical
expertise; they are also relatively expensive when applied to
surveillance activities. In addition, a significant limitation of
these tests is their considerable variability (CVs of up to 33%)
between runs and between different laboratories. Conse-
quently, there is the need to institute calibrators and soft-
ware packages for data analysis.5 Also, the necessity to
calculate new control ranges each time a new kit lot is used
adds to the rigors of the procedure. In addition to a less than
perfect sensitivity for correctly classifying infections,1 the
widely used DV S/LS test requires stable electricity for
incubators, plate readers, and washers, expertise for per-
forming the test, maintenance provisions for instruments,
and has a relatively high cost. Similarly, the newly marketed
BED capture EIA (BED CEIA) involves multiple incubations,
requires instrumentation, a freezer for storing some
reagents, and even a balance for weighing reagents.
Table 2 provides a comparison of the major parameters of
EIA S/LS tests and the PA LS test.
The utility of rapid HIV S/LS assays has been reported,1,6
and these tests exploit the same principle of antibody titer
for differentiating recent from established infections. How-
ever, the findings of Constantine et al. showed that a rapid
test method had a high misclassification rate (17%), although
test indices could be improved if coupled with the results of
the DV test.1 In a study by Soroka et al.,6 three rapid HIV tests
were evaluated for their ability to identify recent infections
by optimizing the sample dilution and comparing test results
with samples previously characterized by the Abbott 3A11 S/usly described in the literature
CEIA Serodia PA-LS
1 Not required
1 Not required
1 1:40 000
t 37 8C 6 h—48 h at room temperature
Not required
t 37 8C Not required
Not required
in at 25 8C Not required
ired Not required
ediately Between 6 and 48 h
ired Not required
<0.8 Visual (no agglutination)
ell EIA plate Non-transparent 96-well EIA plate
No
2
1
5—$11 ($2.75 per well) $0.10
cal density; ODn = normalized optical density.
464 H. Li et al.LS test. The concordance values of these rapid tests with the
Abbott 3A11 S/LS were all greater than 94%. However, the
accuracy of these rapid tests for classifying samples was not
assessed because samples with known times of infection were
not used.
A concern of S/LS EIAs and rapid tests is their subtype B-
dependent performance, which could significantly limit their
use inmany parts of the world. This was addressed in the BED-
CEIA by using a highly conserved multi-subtype (clades B, E
and D) derived branched gp41 peptide in an IgG capture
format.11,13 Although this S/LS test was validated in locations
where different HIV clades exist, concern exists that it may
overestimate incidence. Indeed, the Epidemiology Reference
Group Secretariat at UNAIDS has recommended in December
2005 that the BED assay not be used for incidence estimates,
and called for ‘‘exploring alternative laboratory assays’’.14
The Serodia HIV-1/2 particle agglutination assay is widely
used in many parts of the world, is simple to perform, and is
an inexpensive assay that does not require instrumentation.
Also, it incorporates a viral lysate antigen that may be
effective in detecting antibodies to non-B clades.15,16
Because of these advantages, the test was selected and
modified to act as an S/LS assay. The PA-LS test procedure
involves only two steps: (1) dilution of samples and antigen,
and (2) addition of samples and antigen into reaction wells.
The assay does not require any washing steps, preparation of
reagents (other than antigen dilution), or multiple incuba-
tions; there is only one incubation step conducted at room
temperature, and no instruments or equipment are required
to perform the PA-LS test. Results are read after 6 hours, but
are stable for up to 48 hours, allowing a convenient overnight
incubation before interpretation.
The results using the PA-S (sensitive mode) showed that
the modifications to the Serodia HIV-1/2 PA test did not result
in a loss of sensitivity or specificity; therefore, it could be
used for routine HIV testing while offering a significant cost
saving (>50 times). However, because false positive results
were observed in 12 out of 990 HIV-1 negative samples, it is
recommended that laboratories that choose to use the PA-S
as the screening test should test all samples with the unsen-
sitized particles, or should re-test only those samples that are
reactive on the PA-S using unsensitized particles to identify
false positive result that are due to non-specific reaction to
the gelatin particles. Also, it is important to use only HIV
confirmed positive samples when performing S/LS testing
because false positive samples may cause an overestimation
of recent infection (false-positive recents).
The PA-LS test was successfully calibrated as an S/LS test
strategy, as evidenced by its excellent performance when
testing 37 seroconversion panels consisting of 309 samples
with known times of infection. The test correctly identified
97.1% and 96.6% of samples from persons with recent and
established infections, respectively. Although a preliminary
analysis of this data set showed that 1/25 (4%) of AIDS
samples were misclassified as being recent, which is similar
to the 4.3% rate shown in studies with the BED assay,2 future
studies with a larger sample size of AIDS patients would
provide a more definitive misclassification rate. This near-
perfect performance occurred with a selected window period
of 190 days, notmuch different from that of other S/LS assays
that have window periods ranging from 133 to 170 days. We
selected this window period to yield the best collectiveperformance with all samples. Surprisingly, a poor concor-
dance was observed between the performances of the DV S/
LS test and the PA-LS using a subset of 25 seroconversion
panels. This was evidently because of the poor accuracy of
the DV S/LS test, where only 83% of recent and 54% of
established infection samples were correctly classified.
The reason for this poor performance is unknown. When
single specimens were selected from each panel (n = 37)
and analyzed by the PA-LS as independent points that might
mirror a true cross-sectional testing situation, the PA-LS
correctly classified 100% of all specimens (recent and estab-
lished). The optimal predictive value of the PA-LS to correctly
detect known recent infections (190 days) was 99% at the
1:20 000 dilution; however, 10.7% of known recent samples
were misclassified (data not shown).
To determine the PA-LS test’s ability to accurately dis-
criminate samples close to the 190-day window period, the
analysis also included four specimens that were around the
190 days post-seroconversion cutoff. With respect to the
reproducibility of test results, the PA-LS exhibited 100%
reproducibility, thereby suggesting no need for repeat test-
ing. In addition, the interpretation of results was consistent
when read by different operators.
There are three disadvantages of the PA-LS test, however.
First, the reagents do require refrigeration, whichmight limit
its use in some laboratories without stable electricity. Sec-
ond, as with most S/LS assays, the test requires a number of
dilutions to arrive at the 1:40 000 sample dilution, a man-
euver that requires good pipetting technique. Third, the viral
lysate antigen is derived from HIV clade B and the test has not
been validated with sera from non-B clades. To address issues
related to quality assurance and quality control when per-
forming the PA-LS test, it may be necessary to include a
calibrator or other means to ensure that the test is perform-
ing as expected with all users and in all testing venues. Such
needs are usually determined and incorporated by a manu-
facturer at the time of commercialization to ensure that all
users attain a high degree of confidence in the performance
of the test. The inclusion of a calibrator or quality control
check would verify that users, whether in a centralized or
more remote testing laboratory, are performing the test
correctly.
The most attractive feature of the PA-LS is its extremely
low cost. To understand the potential cost-savings that could
be achieved using the PA-LS test, we determined, as an
example, the cost involved in the measurement of HIV
incidence by testing archived samples previously collected
in a typical sentinel surveillance study. Assuming a sample
size of 50 000 HIV positive samples collected from a survey,
and an estimated 20% rate of recent infection, the BED test
(at $2.75 per test, and triplicate testing of samples initially
classified as being from recent infection) would cost
$220 000, and the DV (at $1 per test, and triplicate testing
of all samples) would cost $150 000. However the PA-LS test
(at $0.10 per test, including the cost of the Dilsim sample
diluent, and only single testing of samples) would cost only
$5 000. This cost-saving (about 30—44-fold) using the PA-LS
will offer a more affordable means to measure and monitor
incidence, identify recently infected persons, and to evalu-
ate the efficiency of intervention programs. Moreover,
laboratory professionals in most parts of the world will not
have difficulty adopting the PA-LS test since most are already
Simple test to determine recent HIV infection 465familiar with the routine Serodia HIV-1/2 PA test, which is
identical to the PA-LS test except for the initial dilution step.
In summary, we have developed a simple serologic assay
that can be used for incidence estimates and identifying
persons who have been recently infected with HIV. The test
is simple to perform, applicable for resource-limited coun-
tries because of its low cost and lack of required instrumen-
tation, and its format is familiar to laboratories throughout
the world. These attributes address the major limitations of
currently used S/LS assays; that is, the ability of the PA-LS
assay to be performed in laboratories that cannot support EIA
technology because of infrastructure or technical expertise
requirements. In conclusion, the attractive features of the
PA-LS, along with its near-perfect performance for differen-
tiating recent from established HIV infection, poise the PA-LS
test to be a practical choice for health organizations and
remote local laboratories, especially in less developed
nations where limited financial and material resources have
to be wisely and systematically allocated to implement HIV
prevention and treatment programs.
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